PURPOSE: To investigate the suitability of short-course radiotherapy (RT) for spinal cord compression (SCC) in myeloma patients. METHODS AND MATERIALS: Data for 172 myeloma patients irradiated between January 1994 and December 2004 for SCC were retrospectively evaluated. Short-course RT (1 x 8 Gy, 5 x 4 Gy, n = 61) and long-course RT (10 x 3 Gy, 15 x 2.5 Gy, 20 x 2 Gy, n = 111) were compared for functional outcome up to 24 months after RT. In addition, 10 potential prognostic factors were investigated. RESULTS: Improvement of motor function occurred in 90 patients (52%). Forty-seven percent of nonambulatory patients regained the ability to walk. Functional outcome was significantly influenced by the time of developing motor deficits before RT. Improvement of motor function was more frequent after long-course RT than after short-course RT: 59% vs. 39% (p = 0.10) at 1 month, 67% vs. 43% (p = 0.043) at 6 months, 76% vs. 40% (p = 0.003) at 12 months, 78% vs. 43% (p = 0.07) at 18 months, and 83% v 54% (p = 0.33) at 24 months. A subgroup analysis of the long-course RT group demonstrated a similar functional outcome for 10 x 3 Gy when compared with 15 x 2.5 Gy and 20 x 2 Gy. CONCLUSIONS: Long-course RT is preferable for SCC in myeloma patients because it resulted in better functional outcome than short-course RT. Treatment with 10 x 3 Gy can be considered appropriate.
PURPOSE: To investigate the suitability of short-course radiotherapy (RT) for spinal cord compression (SCC) in myelomapatients. METHODS AND MATERIALS: Data for 172 myelomapatients irradiated between January 1994 and December 2004 for SCC were retrospectively evaluated. Short-course RT (1 x 8 Gy, 5 x 4 Gy, n = 61) and long-course RT (10 x 3 Gy, 15 x 2.5 Gy, 20 x 2 Gy, n = 111) were compared for functional outcome up to 24 months after RT. In addition, 10 potential prognostic factors were investigated. RESULTS: Improvement of motor function occurred in 90 patients (52%). Forty-seven percent of nonambulatory patients regained the ability to walk. Functional outcome was significantly influenced by the time of developing motor deficits before RT. Improvement of motor function was more frequent after long-course RT than after short-course RT: 59% vs. 39% (p = 0.10) at 1 month, 67% vs. 43% (p = 0.043) at 6 months, 76% vs. 40% (p = 0.003) at 12 months, 78% vs. 43% (p = 0.07) at 18 months, and 83% v 54% (p = 0.33) at 24 months. A subgroup analysis of the long-course RT group demonstrated a similar functional outcome for 10 x 3 Gy when compared with 15 x 2.5 Gy and 20 x 2 Gy. CONCLUSIONS: Long-course RT is preferable for SCC in myelomapatients because it resulted in better functional outcome than short-course RT. Treatment with 10 x 3 Gy can be considered appropriate.
Authors: Zain A Husain; Arjun Sahgal; Eric L Chang; Pejman Jabehdar Maralani; Charlotte D Kubicky; Kristin J Redmond; Charles Fisher; Ilya Laufer; Simon S Lo Journal: CNS Oncol Date: 2017-07-18
Authors: Adnan Elhammali; Behrang Amini; Ethan B Ludmir; Jillian R Gunther; Sarah A Milgrom; Chelsea C Pinnix; Therese Andraos; Alison Yoder; Donna Weber; Robert Orlowski; Elisabet Manasanch; Krina Patel; Paolo Strati; Ranjit Nair; Hans C Lee; Sheeba Thomas; Swaminathan Iyer; Gregory Kaufmann; Naveen Garg; Bouthaina S Dabaja Journal: Haematologica Date: 2020-01-09 Impact factor: 9.941
Authors: D Rades; S Douglas; T Veninga; P Poortmans; A Bajrovic; P J Hoskin; V Rudat; S E Schild Journal: Strahlenther Onkol Date: 2012-03-14 Impact factor: 3.621
Authors: Evangelos Terpos; Gareth Morgan; Meletios A Dimopoulos; Matthew T Drake; Suzanne Lentzsch; Noopur Raje; Orhan Sezer; Ramón García-Sanz; Kazuyuki Shimizu; Ingemar Turesson; Tony Reiman; Artur Jurczyszyn; Giampaolo Merlini; Andrew Spencer; Xavier Leleu; Michele Cavo; Nikhil Munshi; S Vincent Rajkumar; Brian G M Durie; G David Roodman Journal: J Clin Oncol Date: 2013-05-20 Impact factor: 44.544
Authors: Jeremy G Price; Donna Niedzwiecki; Taofik Oyekunle; Murat O Arcasoy; Colin E Champ; Chris R Kelsey; Joseph K Salama; Michael J Moravan Journal: Adv Radiat Oncol Date: 2021-05-28
Authors: M Oertel; K Elsayad; R Engenhart-Cabillic; G Reinartz; C Baues; H Schmidberger; D Vordermark; S Marnitz; P Lukas; C Ruebe; A Engert; G Lenz; H T Eich Journal: Strahlenther Onkol Date: 2020-10-30 Impact factor: 3.621